Corbin KD, Dagogo-Jack S, Cannon CP, Cherney DZI, et al. Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease - analyses from VERTIS CV, a randomized trial of the SGLT2 inhibitor ertugliflozin. Diabetes Obes Metab 2022 Nov 17. doi: 10.1111/dom.14923.
PMID: 36394384